Market news

CAMBRIDGE, Mass., September 23, 2026--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

CAMBRIDGE, Mass., September 08, 2026--Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Detailed price information for Amylyx Pharmaceuticals Inc (AMLX-Q) from The Globe and Mail including charting and trades.

The biotech delivered excellent news from the laboratory.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has released topline results from the Phase 3 LUCIDITY trial of avexitide on August 18, 2026. Shares closed Monday down 0.9% at $21.43, then traded 15.7% higher at $24.80 after hours after the company scheduled the readout. The rally came before investors saw any efficacy or safety data, underscoring how much […]

Detailed price information for Moderna Inc (MRNA-Q) from The Globe and Mail including charting and trades.

CAMBRIDGE, Mass., August 20, 2026--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,113,500 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the sha

Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.

Amylyx Pharmaceuticals (NasdaqGS: AMLX) reported overwhelmingly positive topline Phase 3 results for avexitide in post-bariatric hypoglycemia, with the trial meeting its primary and all secondary endpoints. The data support a planned NDA filing for avexitide in PBH, a condition that currently has no FDA-approved therapies. Alongside the clinical update, Amylyx completed a substantial follow-on public equity offering to fund pre-commercial work and broader R&D efforts. For more context on...

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) soared to a new three-year high on Tuesday after its treatment candidate for post-bariatric hypoglycemia (PBH) reported strong results in phase 3 clinical studies, paving the way for its looming commercialization. In intra-day trading, the stock surged to a record of $35.39 before trimming a few cents to end the session […]

GLP-1 drugs aren't just for weight loss.

The capital raise comes as Amylyx prepares to move from clinical success toward potential commercialization, following the positive trial data for avexitide announced earlier today.

Amylyx shares rally on promising avexitide, a GLP-1 receptor antagonist, data. But should you load up on AMLX stock on strength today? Let’s find out!

CAMBRIDGE, Mass., August 18, 2026--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In addition, Amylyx intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares of common stock are being

Patients on avexitide experienced 55% fewer severe hypoglycemic events than those on a placebo in the late-stage study

Amylyx Pharmaceuticals, Inc. upgraded to Strong Buy after phase 3 LUCIDITY avexitide PBH results. Click for this AMLX stock update and see why I am upgrading it.

2026-08-18. The following slide deck was published by Amylyx Pharmaceuticals, Inc.

Here are some of the companies making headlines in midday trading.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) reported positive topline results from its Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia, with the study meeting its FDA-agreed primary endpoint and all secondary endpoints.

Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III LUCIDITY trial of avexitide met its primary endpoint, reducing the composite rate of clinically significant hypoglycemic events by 55% versus placebo in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery. The ra

Amylyx stock skyrocketed Tuesday after its GLP-1 drug reduced hypoglycemia in patients who've undergone bariatric surgery.

Amylyx Pharmaceuticals (AMLX) stock is expected to rise as the company reports a late-stage trial win for its GLP-1 receptor antagonist avexitide. Read more here.

CAMBRIDGE, Mass., August 18, 2026--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced positive topline results from LUCIDITY, a 78-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surg

A late-stage trial found the drug, which Amylyx bought for cheap in a bankruptcy auction, was effective at regulating blood sugar in patients who’d just undergone bariatric surgery.

Amylyx Pharmaceuticals stock has delivered a 170.4% return over the past year, yet its valuation checks and market multiples suggest the shares are not obviously cheap. After this strong run, investors are facing a stock that screens as expensive on several metrics, despite the momentum. Amylyx Pharmaceuticals is up 170.4% over the last year, which puts extra focus on whether the current share price still lines up with the company’s fundamentals. Progress with avexitide, including the...

Amylyx Pharmaceuticals (AMLX) stock is in focus after the company reported a Q2 2026 net loss of US$43.42 million and a basic loss per share of US$0.39 from continuing operations. See our latest analysis for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals shares have pulled back in the very short term, with a 1-day share price return of 3.78% and 7-day share price return of 5.21%. These moves sit against a much stronger 30-day share price return of 21.65%, 90-day share price return of 62.82%,...